Vista Pharmaceuticals Ltd Stock Price Today (NSE: VISTAPH)
Fundamental Score
Vista Pharmaceuticals Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Vista Pharmaceuticals Ltd share price today is ₹8.00, up +0.00% on NSE/BSE as of 19 June 2026. Vista Pharmaceuticals Ltd (VISTAPH) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹52.93 (Cr). The 52-week high for VISTAPH share price is ₹11.69 and the 52-week low is ₹5.71. The company has a Return on Equity (ROE) of -10.83% and a debt-to-equity ratio of 0.19.
Vista Pharmaceuticals Ltd Share Price Chart — NSE/BSE Historical Performance
Vista Pharmaceuticals Ltd share price chart: -0.37% return over the past month. 52-week high ₹11.69, 52-week low ₹5.71.
Vista Pharmaceuticals Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹7.80 | ₹8.60 | ₹7.80 | ₹8.00 | 60.05K (Cr) | |
| ₹6.85 | ₹7.76 | ₹6.85 | ₹7.63 | 21.53K (Cr) | |
| ₹7.30 | ₹7.32 | ₹6.90 | ₹7.27 | 11.11K (Cr) | |
| ₹7.15 | ₹7.32 | ₹7.02 | ₹7.32 | 12.36K (Cr) | |
| ₹7.45 | ₹7.45 | ₹7.10 | ₹7.35 | 1.30K (Cr) | |
| ₹6.90 | ₹7.46 | ₹6.83 | ₹7.46 | 1.46K (Cr) | |
| ₹7.16 | ₹7.68 | ₹7.16 | ₹7.22 | 4.54K (Cr) | |
| ₹7.75 | ₹7.75 | ₹7.04 | ₹7.26 | 6.36K (Cr) | |
| ₹7.25 | ₹7.79 | ₹7.25 | ₹7.30 | 7.85K (Cr) | |
| ₹7.79 | ₹7.84 | ₹7.10 | ₹7.25 | 15.37K (Cr) |
Vista Pharmaceuticals Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹7.80 | ₹8.60 | ₹6.83 | ₹8.00 | +2.56% | |
| ₹6.11 | ₹8.55 | ₹6.05 | ₹7.74 | +26.68% | |
| ₹6.90 | ₹8.87 | ₹5.71 | ₹6.11 | -11.45% | |
| ₹8.29 | ₹8.50 | ₹6.60 | ₹6.90 | -16.77% | |
| ₹8.20 | ₹8.84 | ₹7.00 | ₹7.20 | -12.20% | |
| ₹8.94 | ₹9.90 | ₹7.90 | ₹8.14 | -8.95% | |
| ₹9.90 | ₹10.10 | ₹7.63 | ₹8.86 | -10.51% | |
| ₹10.07 | ₹10.50 | ₹9.17 | ₹9.82 | -2.48% | |
| ₹9.96 | ₹10.75 | ₹9.30 | ₹9.87 | -0.90% | |
| ₹10.79 | ₹11.45 | ₹9.38 | ₹9.95 | -7.78% | |
| ₹11.27 | ₹11.69 | ₹10.22 | ₹10.51 | -6.74% | |
| ₹10.12 | ₹10.85 | ₹10.00 | ₹10.84 | +7.11% |
AI Research Briefing
Powered by Gemini · 2026-04-09
USFDA approval doesn't matter when you can't convert sales into profit.
WHAT'S HAPPENING NOW (last 2-4 weeks)
No major catalysts found after live search. Vista Pharmaceuticals posted a Q3 net loss of Cr. The company's revenue also fell by 6.34% compared to the same period last year.
CORE STORY (THE REAL GAME)
Vista Pharma is a micro-cap play on generic drug manufacturing, specifically tablets and capsules, with a USFDA-approved facility. The market seems to be pricing in a turnaround story based on potential export growth and manufacturing capabilities, despite current losses and negative growth.
- USFDA approved facility
- Indian pharma sector growth
- Low base effect
- Significant order wins
- Return to profitability
- Increase in promoter holding
- Consistent losses
- Negative growth
- Low promoter holding
FII and DII holdings are negligible, indicating a lack of institutional interest.
Indian pharma sector is growing, but US pricing pressure remains a headwind.
Negative free cash flow of ₹-24.15 Cr over the last 5 years.
If Vista can't demonstrate revenue growth and achieve profitability in the next 2-3 quarters, expect a significant correction. The company needs to show concrete signs of a turnaround to justify its current valuation.
Primary Thesis Risk
Inability to achieve profitability will lead to stock collapse.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Vista Pharmaceuticals Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Vista Pharmaceuticals Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of VISTAPH across key market metrics for learning purposes.
Positive Indicators
2 factors identified
Conservative Debt Levels (D/E: 0.19)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
13 factors identified
Below-Average Return on Equity (-10.83%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (-8.53%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Margin Pressure Concerns (-64.82%)
Observation: Operating margins are below industry standards.
Analysis: OPM <5% may indicate pricing pressures or cost management challenges.
Profit Decline Concern (-167.01%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Revenue Contraction (-41.37%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions.
Limited Growth History (-15.53% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.
Weak Earnings Growth (-0.87% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Stagnant Profit Growth (-5.94% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity.
Weak Interest Coverage (-8.96x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Negative Free Cash Flow (₹-24.15 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Low Promoter Commitment (21.19%)
Observation: Reduced promoter stake may indicate limited confidence.
Analysis: Low promoter holding may raise questions about management commitment.
Limited Institutional Interest (FII+DII: 0.02%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Vista Pharmaceuticals Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Vista Pharmaceuticals Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Vista Pharmaceuticals LtdVista Pharmaceu...Selected✓ VISTAPH • 524711 | 0/100 | ₹8.00₹8 | ₹52.93₹52.93 | — — | -10.83%Poor -10.83% Poor | -8.53%Poor -8.53% Poor | 0.19Excellent 0.2 Excellent | -5.94%Poor -5.94% Poor | -15.53%Poor -15.53% Poor | 0.00% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 65.2/100 | ₹1844.30₹1844 | ₹433738.68₹433738.68 | 37.57Average 37.6 Average | 16.86%Good 16.86% Good | 20.21%Excellent 20.21% Excellent | 0.07Excellent 0.1 Excellent | 23.78%Excellent 23.78% Excellent | 9.87%Good 9.87% Good | 0.89% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 67.9/100 | ₹6797.50₹6798 | ₹170445.88₹170445.88 | 68.59Average 68.6 Average | 15.35%Good 15.35% Good | 20.44%Excellent 20.44% Excellent | 0.01Excellent 0.0 Excellent | 10.41%Good 10.41% Good | 11.65%Good 11.65% Good | 0.47% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 65.3/100 | ₹4537.80₹4538 | ₹126430.62₹126430.62 | 58.36Average 58.4 Average | 26.52%Excellent 26.52% Excellent | 27.05%Excellent 27.05% Excellent | 0.33Excellent 0.3 Excellent | 13.84%Good 13.84% Good | 7.72%Good 7.72% Good | 0.86% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 59/100 | ₹1418.20₹1418 | ₹123059.76₹123059.76 | 22.62Average 22.6 Average | 17.77%Good 17.77% Good | 22.72%Excellent 22.72% Excellent | 0.01Excellent 0.0 Excellent | 28.68%Excellent 28.68% Excellent | 9.97%Good 9.97% Good | 0.85% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 59.2/100 | ₹1319.00₹1319 | ₹105224.96₹105224.96 | 18.23Average 18.2 Average | 17.96%Good 17.96% Good | 22.69%Excellent 22.69% Excellent | 0.16Excellent 0.2 Excellent | 22.28%Excellent 22.28% Excellent | 13.26%Good 13.26% Good | 0.63% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 66.7/100 | ₹2276.40₹2276 | ₹95148.15₹95148.15 | 22.00Average 22.0 Average | 20.62%Excellent 20.62% Excellent | 21.30%Excellent 21.30% Excellent | 0.32Excellent 0.3 Excellent | 54.88%Excellent 54.88% Excellent | 8.11%Good 8.11% Good | 0.58% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 68.7/100 | ₹956.95₹957 | ₹94253.78₹94253.78 | 18.74Average 18.7 Average | 21.21%Excellent 21.21% Excellent | 24.31%Excellent 24.31% Excellent | 0.38Excellent 0.4 Excellent | 25.92%Excellent 25.92% Excellent | 10.27%Good 10.27% Good | 1.17% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 50.6/100 | ₹2420.40₹2420 | ₹92012.53₹92012.53 | 52.62Average 52.6 Average | 14.68%Average 14.68% Average | 15.98%Good 15.98% Good | 0.55Good 0.6 Good | 11.73%Good 11.73% Good | 15.79%Excellent 15.79% Excellent | 0.04% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 28.8/100 | ₹1435.90₹1436 | ₹70798.69₹70798.69 | 20.69Average 20.7 Average | 11.08%Average 11.08% Average | 14.18%Average 14.18% Average | 0.22Excellent 0.2 Excellent | 3.87%Average 3.87% Average | 6.55%Good 6.55% Good | 0.33% |
Alkem Laboratories LtdAlkem Laborator... ALKEM • 539523 | 59.5/100 | ₹5451.50₹5452 | ₹67075.29₹67075.29 | 28.54Average 28.5 Average | 19.39%Good 19.39% Good | 20.38%Excellent 20.38% Excellent | 0.18Excellent 0.2 Excellent | 13.93%Good 13.93% Good | 9.21%Good 9.21% Good | 0.80% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price433738.68 Cr
- Divis Laboratories Ltd share price170445.88 Cr
- Torrent Pharmaceuticals Ltd share price126430.62 Cr
- Cipla Ltd share price123059.76 Cr
- Dr Reddys Laboratories Ltd share price105224.96 Cr
Vista Pharmaceuticals Ltd Quarterly Performance
Latest quarterly metrics for VISTAPH — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
-41.37%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-167.01%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
-15.53%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
-5.94%
Compounded annual net profit growth over 5 years
Vista Pharmaceuticals Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for VISTAPH — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Vista Pharmaceuticals Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Vista Pharmaceuticals Ltd (VISTAPH) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Vista Pharmaceuticals Ltd
About VISTAPH (Vista Pharmaceuticals Ltd)
Vista Pharmaceuticals Ltd is a dynamic and globally-focused pharmaceutical company committed to developing, manufacturing, and distributing high-quality, affordable healthcare solu...tions. With a foundation built on decades of expertise, VISTAPH operates at the intersection of innovation and accessibility, striving to improve patient outcomes through a diverse portfolio of pharmaceutical products. The company's strength lies in its integrated approach, encompassing research and development, rigorous quality control, and a customer-centric distribution network that spans both domestic and international markets. VISTAPH's commitment to excellence is reflected in its state-of-the-art manufacturing facilities and adherence to stringent regulatory standards, ensuring the safety and efficacy of its products. VISTAPH's product range includes a wide array of prescription and over-the-counter generic medications, designed to address a broad spectrum of therapeutic needs. From cardiovascular health to pain management and infectious diseases, VISTAPH offers solutions in the form of tablets, capsules, and liquid formulations, catering to diverse patient preferences and requirements. The company's focus on generic drugs allows it to provide cost-effective alternatives to branded medications, making healthcare more accessible to a wider population. This commitment to affordability does not compromise on quality; each product undergoes thorough testing and quality assurance protocols to meet the highest industry standards. Headquartered in Hyderabad, India, VISTAPH leverages its strategic location and skilled workforce to serve a global clientele. The company is dedicated to fostering innovation and expanding its product pipeline to address unmet medical needs. VISTAPH continually invests in research and development activities, exploring new formulations and drug delivery systems to enhance therapeutic efficacy and patient compliance. Furthermore, the company is actively pursuing strategic partnerships and collaborations to expand its reach and market presence, solidifying its position as a trusted provider of pharmaceutical solutions worldwide.
Company Details
Key Leadership
VISTAPH Share Price: Frequently Asked Questions
What is the current share price of Vista Pharmaceuticals Ltd?
Vista Pharmaceuticals Ltd (VISTAPH) trades at ₹8.00 on NSE and BSE. Market cap ₹52.93 (Cr). Educational data only.
What is the P/E ratio of Vista Pharmaceuticals Ltd?
Vista Pharmaceuticals Ltd has a P/E of N/Ax vs industry average 31.77x.
What is the Bull Run score for Vista Pharmaceuticals Ltd?
Vista Pharmaceuticals Ltd has a Bull Run score of 0/100 based on 25+ financial parameters.
Does Vista Pharmaceuticals Ltd pay dividends?
Vista Pharmaceuticals Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Vista Pharmaceuticals Ltd?
Vista Pharmaceuticals Ltd has ROE of -10.83%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Vista Pharmaceuticals Ltd?
Vista Pharmaceuticals Ltd has debt-to-equity of 0.19.
Is Vista Pharmaceuticals Ltd a good investment?
Bull Run gives Vista Pharmaceuticals Ltd a score of 0/100. This is not investment advice — consult a SEBI-registered advisor.